First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the […]
V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investors Oncode Oncology Bridge Fund, Swanbridge and BOM Flindr discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations Lead asset is a […]
Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a […]
Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]
HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranches Cumulative royalties sold are capped at a maximum value Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative […]
